Browsing Clinical Studies by author "Griffin, Clare"
Now showing items 1-20 of 32
-
A Dosimetric Comparison of Breast Radiotherapy Techniques to Treat Locoregional Lymph Nodes Including the Internal Mammary Chain.
Ranger, A; Dunlop, A; Hutchinson, K; Convery, H; Maclennan, MK; et al. (ELSEVIER SCIENCE LONDON, 2018-06-01)AIMS: Radiotherapy target volumes in early breast cancer treatment increasingly include the internal mammary chain (IMC). In order to maximise survival benefits of IMC radiotherapy, doses to the heart and lung should be ... -
A multicentre study of the evidence for customized margins in photon breast boost radiotherapy.
Harris, EJ; Mukesh, MB; Donovan, EM; Kirby, AM; Haviland, JS; et al. (BRITISH INST RADIOLOGY, 2016-01-01)OBJECTIVE: To determine if subsets of patients may benefit from smaller or larger margins when using laser setup and bony anatomy verification of breast tumour bed (TB) boost radiotherapy (RT). METHODS: Verification imaging ... -
A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer.
Murray, J; Griffin, C; Gulliford, S; Syndikus, I; Staffurth, J; et al. (ELSEVIER IRELAND LTD, 2020-01-01)BACKGROUND AND PURPOSE: Image-guided radiotherapy (IGRT) improves treatment set-up accuracy and provides the opportunity to reduce target volume margins. We introduced IGRT methods using standard (IGRT-S) or reduced (IGRT-R) ... -
A randomized control trial evaluating fluorescent ink versus dark ink tattoos for breast radiotherapy.
Landeg, SJ; Kirby, AM; Lee, SF; Bartlett, F; Titmarsh, K; et al. (BRITISH INST RADIOLOGY, 2016-12-01)OBJECTIVE: The purpose of this UK study was to evaluate interfraction reproducibility and body image score when using ultraviolet (UV) tattoos (not visible in ambient lighting) for external references during breast/chest ... -
Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial.
Brunt, AM; Wheatley, D; Yarnold, J; Somaiah, N; Kelly, S; et al. (ELSEVIER IRELAND LTD, 2016-07-15)BACKGROUND AND PURPOSE: FAST-Forward is a phase 3 clinical trial testing a 1-week course of whole breast radiotherapy against the UK standard 3-week regimen after primary surgery for early breast cancer. Two acute skin ... -
Acute Toxicity of Hypofractionated and Conventionally Fractionated (Chemo)Radiotherapy Regimens for Bladder Cancer: An Exploratory Analysis from the RAIDER Trial.
Huddart, R; Hafeez, S; Omar, A; Alonzi, R; Birtle, A; et al. (ELSEVIER SCIENCE LONDON, 2023-05-01)AIMS: Adding concurrent (chemo)therapy to radiotherapy improves outcomes for muscle-invasive bladder cancer patients. A recent meta-analysis showed superior invasive locoregional disease control for a hypofractionated 55 ... -
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Dearnaley, D; Syndikus, I; Mossop, H; Khoo, V; Birtle, A; et al. (ELSEVIER SCIENCE INC, 2016-08-01)BACKGROUND: Prostate cancer might have high radiation-fraction sensitivity that would give a therapeutic advantage to hypofractionated treatment. We present a pre-planned analysis of the efficacy and side-effects of a ... -
Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trial.
Nutting, CM; Griffin, CL; Sanghera, P; Foran, B; Beasley, M; et al. (ELSEVIER SCI LTD, 2021-08-01)BACKGROUND: Radical (chemo)radiotherapy offers potentially curative treatment for patients with locally advanced laryngeal or hypopharyngeal cancer. We aimed to show that dose-escalated intensity-modulated radiotherapy ... -
Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial.
Coles, CE; Haviland, JS; Kirby, AM; Griffin, CL; Sydenham, MA; et al. (ELSEVIER SCIENCE INC, 2023-06-24)BACKGROUND: A tumour-bed boost delivered after whole-breast radiotherapy increases local cancer-control rates but requires more patient visits and can increase breast hardness. IMPORT HIGH tested simultaneous integrated ... -
Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trial.
Murray, J; Gulliford, S; Griffin, C; Wilkins, A; Syndikus, I; et al. (ELSEVIER IRELAND LTD, 2020-03-01)BACKGROUND AND PURPOSE: The penile bulb (PB) dose may be critical in development of post prostate radiotherapy erectile dysfunction (ED). This study aimed to generate PB dose constraints based on dose-volume histograms ... -
Failing to Close the Gap Between Evidence and Clinical Practice in Radical Bladder Cancer Radiotherapy.
Hafeez, S; Lewis, R; Griffin, C; Hall, E; Huddart, R (ELSEVIER SCIENCE LONDON, 2021-01-01) -
Forward- and Inverse-Planned Intensity-Modulated Radiotherapy in the CHHiP Trial: A Comparison of Dosimetry and Normal Tissue Toxicity.
Naismith, OF; Griffin, C; Syndikus, I; South, C; Mayles, H; et al. (ELSEVIER SCIENCE LONDON, 2019-09)AIMS: The CHHiP (Conventional or Hypofractionated High-dose Intensity Modulated Radiotherapy In Prostate Cancer; CRUK/06/016) trial investigated hypofractionated radiotherapy for localised prostate cancer. Forward- (FP) ... -
How informed is declared altruism in clinical trials? A qualitative interview study of patient decision-making about the QUEST trials (Quality of Life after Mastectomy and Breast Reconstruction).
Bidad, N; MacDonald, L; Winters, ZE; Edwards, SJL; Emson, M; et al. (BMC, 2016-09-02)BACKGROUND: Randomised controlled trials (RCTs) often fail to recruit sufficient participants, despite altruism being cited as their motivation. Previous investigations of factors influencing participation decisions have ... -
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Wilkins, A; Mossop, H; Syndikus, I; Khoo, V; Bloomfield, D; et al. (ELSEVIER SCIENCE INC, 2015-12-01)BACKGROUND: Patient-reported outcomes (PROs) might detect more toxic effects of radiotherapy than do clinician-reported outcomes. We did a quality of life (QoL) substudy to assess PROs up to 24 months after conventionally ... -
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand, DH; Tree, AC; Ostler, P; van der Voet, H; Loblaw, A; et al. (ELSEVIER SCIENCE INC, 2019-09-17)BACKGROUND: Localised prostate cancer is commonly treated with external-beam radiotherapy. Moderate hypofractionation has been shown to be non-inferior to conventional fractionation. Ultra-hypofractionated stereotactic ... -
Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer.
Wilkins, AC; Gusterson, B; Szijgyarto, Z; Haviland, J; Griffin, C; et al. (ELSEVIER SCIENCE INC, 2018-06-01)PURPOSE: To assess whether the cellular proliferation marker Ki67 provides prognostic information and predicts response to radiation therapy fractionation in patients with localized prostate tumors participating in a ... -
Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials.
Haviland, JS; Mannino, M; Griffin, C; Porta, N; Sydenham, M; et al. (ELSEVIER IRELAND LTD, 2018-01-01)BACKGROUND AND PURPOSE: Adjuvant lymphatic radiotherapy (LNRT) is recommended for selected axillary node positive women with early breast cancer. We investigated whether hypofractionated LNRT is safe combined with ... -
Linkage of the CHHiP randomised controlled trial with primary care data: a study investigating ways of supplementing cancer trials and improving evidence-based practice.
Lemanska, A; Byford, RC; Cruickshank, C; Dearnaley, DP; Ferreira, F; et al. (BMC, 2020-07-25)BACKGROUND: Randomised controlled trials (RCTs) are the gold standard for evidence-based practice. However, RCTs can have limitations. For example, translation of findings into practice can be limited by design features, ... -
Linking CHHiP prostate cancer RCT with GP records: A study proposal to investigate the effect of co-morbidities and medications on long-term symptoms and radiotherapy-related toxicity.
Lemanska, A; Byford, RC; Correa, A; Cruickshank, C; Dearnaley, DP; et al. (Elsevier BV, 2017-06-27)BACKGROUND: Patients receiving cancer treatment often have one or more co-morbid conditions that are treated pharmacologically. Co-morbidities are recorded in clinical trials usually only at baseline. However, co-morbidities ... -
Multi-candidate immunohistochemical markers to assess radiation response and prognosis in prostate cancer: results from the CHHiP trial of radiotherapy fractionation.
Wilkins, A; Gusterson, B; Tovey, H; Griffin, C; Stuttle, C; et al. (ELSEVIER, 2023-02-01)BACKGROUND: Protein markers of cellular proliferation, hypoxia, apoptosis, cell cycle checkpoints, growth factor signalling and inflammation in localised prostate tumours have previously shown prognostic ability. A ...